Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

http://www.reportlinker.com/p0799192/Pediatric-Vaccines-Market-to-2017--Strategic-Focus-on-Partnering-as-Licensing-and-Co-Development-Accounted-for-69%-of-Deal-Making-Activity-from-2004-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011", which provides insights into global pediatric vaccines market forecast until 2017. The report provides an in-depth analysis of six vaccines which include hepatitis A, hepatitis B, polio, rotavirus, Mumps, Measles and Rubella (MMR) and Diphtheria, Tetanus and Pertussis (DTaP). The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines Research and Development (R&D) pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis shows that the overall global pediatric vaccines market was valued at $14 billion in 2010. The market is expected to witness a growth at a CAGR of 11.5% for the forecast period and will reach $24.3 billion by 2017. The global market revenues are expected to increase due to the introduction of new molecules which are currently in the regulatory filing stage and those in the later stages of development. The top pharmaceutical companies in the vaccines market are – GlaxoSmithKline, Sanofi, Pfizer, Novartis AG., Merck & co. Inc and SP-MSD. Approximately 88% of the market is covered by the above six companies.

Scope

- Data and analysis on the global pediatric vaccines market

- Annualized market data for the vaccines market from 2007 to 2017

- Key drivers and restraints that have had a significant impact on the market

- The competitive landscape of the global vaccines market

- Key M&A activities, licensing agreements and co-development deals that took place in the pediatric vaccines market

Reasons to buy

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.

- Device a more tailored country strategy through the understanding of key drivers and barriers of vaccines market.

- Develop key strategic initiatives by understanding the key focus areas and leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 8

2 Pediatric Vaccines Market to 2017 - Introduction 10

2.1 GBI Research Report Guidance 11

3 Pediatric Vaccines Market to 2017 - Market Overview 12

3.1 Vaccine Preventable Diseases 12

3.2 Vaccine Manufacturing Process 13

3.3 Determinants of Immunization Coverage 13

3.3.1 Immunization Programs 13

3.3.2 Public Private Partnerships 14

3.3.3 Production Capacity 14

3.3.4 Reimbursements 14

4 Pediatric Vaccines Market to 2017 - Global Vaccine Market 15

4.1 Market Forecasts 15

4.1.1 Market Share by Disease Sector 16

4.1.2 Market Share by Geography 17

4.2 Average Cost of Vaccination per Child 17

4.3 Target Population 18

4.3.1 Immunization Coverage 19

4.4 Drivers and Barriers of the Pediatric Vaccines Market 20

4.4.1 Drivers for Pediatric Vaccine Market 20

4.4.2 Barriers for Pediatric Vaccines Market 21

5 Global Pediatric Vaccines Market to 2017 - Geographical Landscape 22

5.1 The US 22

5.1.1 Market Overview 22

5.1.2 Market Forecasts 22

5.1.3 Average Cost of Vaccination 23

5.1.4 Immunization Coverage 25

5.1.5 Immunization Schedule 26

5.1.6 Regulatory Framework 27

5.1.7 Vaccine Procurement 28

5.2 Top Five Countries of Europe 29

5.2.1 Market Overview 29

5.2.2 Market Forecasts 29

5.2.3 Average Cost of Vaccination per Child 30

5.2.4 Immunization Coverage 32

5.2.5 The UK 33

5.2.6 France 34

5.2.7 Germany 35

5.2.8 Italy 36

5.2.9 Spain 37

5.3 Rest of the World 38

5.3.1 Market Overview 38

5.3.2 Market Forecasts 38

5.3.3 Average Cost of Vaccination per Child 39

5.3.4 Immunization Coverage 41

5.3.5 Immunization Schedule 42

5.3.6 Regulatory Framework 42

5.3.7 Vaccine Procurement 42

6 Global Pediatric Vaccines Market to 2017 - Therapeutic Landscape 43

6.1 Hepatitis A 43

6.1.1 Overview 43

6.1.2 Market Forecasts 43

6.1.3 Average Cost of Vaccination 44

6.1.4 Target Population 45

6.1.5 Marketed Products for Hepatitis A 46

6.2 Hepatitis B 48

6.2.1 Overview 48

6.2.2 Market Forecasts 49

6.2.3 Average Cost of Vaccination 50

6.2.4 Target Population 51

6.2.5 Marketed Products for Hepatitis B 52

6.3 Polio 55

6.3.1 Overview 55

6.3.2 Market Forecasts 55

6.3.3 Average Cost of Vaccination 56

6.3.4 Target Population 57

6.3.5 Marketed Products for Polio 58

6.4 Rotavirus 59

6.4.1 Overview 59

6.4.2 Market Forecasts 59

6.4.3 Average Cost of Vaccination 60

6.4.4 Target Population 61

6.4.5 Product Analysis 62

6.4.6 Marketed Products for Rotavirus 62

6.5 DTaP 64

6.5.1 Overview 64

6.5.2 Market Forecasts 64

6.5.3 Average Cost of Vaccination 65

6.5.4 Target Population 66

6.5.5 Marketed Products for DTaP 67

6.6 MMR 69

6.6.1 Overview 69

6.6.2 Market Forecasts 69

6.6.3 Average Cost of Vaccination 70

6.6.4 Target Population 71

6.6.5 Marketed Products for MMR 72

7 Global Pediatric Vaccines Market to 2017 - Product Pipeline Analysis 74

7.1 Research and Development Pipeline by Phase 74

7.2 Research and Development Pipeline by Indication 75

7.3 Research and Development Pipeline - Hepatitis A Vaccines 76

7.3.1 Overview 76

7.3.2 Pipeline by Clinical Phases of Development 77

7.4 Research and Development Pipeline - Hepatitis B Vaccines 77

7.4.1 Overview 77

7.4.2 Pipeline by Clinical Phases of Development 78

7.5 Research and Development Pipeline - Polio Vaccines 83

7.5.1 Overview 83

7.5.2 Pipeline by Clinical Phases of Development 84

7.6 Research and Development Pipeline - Rotavirus Vaccines 86

7.6.1 Overview 86

7.6.2 Pipeline by Clinical Phases of Development 87

7.7 Research and Development Pipeline - DTaP Vaccines 88

7.7.1 Overview 88

7.7.2 Pipeline by Clinical Phases of Development 89

7.8 Research and Development Pipeline - MMR Vaccines 92

7.8.1 Overview 92

7.8.2 Pipeline by Clinical Phases of Development 93

8 Global Pediatric Vaccines Market - Competitive Landscape 94

8.1 Overview 94

8.2 Company Profiling 94

8.2.1 Novartis 94

8.2.2 GlaxoSmithKline (GSK) 96

8.2.3 Sanofi Pasteur MSD 97

8.2.4 Merck 99

8.2.5 Pfizer 100

9 Global Pediatric Vaccines Market to 2017 - Strategic Consolidations 102

9.1 Segmentation by Type 102

9.2 Segmentation by Year 103

9.3 Mergers and Acquisitions 104

9.3.1 Overview 104

9.3.2 M&A Deals by Indication 105

9.3.3 M&A Deals by Year 106

9.3.4 M&A Deals by Geography 107

9.3.5 M&A Deals by Value 108

9.3.6 Major Mergers and Acquisitions (M&A) 109

9.4 Licensing Agreements 110

9.4.1 Overview 110

9.4.2 Licensing Agreements by Indication 110

9.4.3 Licensing Agreements by Year 112

9.4.4 Licensing Agreements by Geography 113

9.4.5 Licensing Agreements by Value 114

9.4.6 Major Licensing Agreements 115

9.5 Co-Development Deals 117

9.5.1 Overview 117

9.5.2 Co-Development Deals by Indication 117

9.5.3 Co-Development Deals by Year 118

9.5.4 Co-Development Deals by Geography 119

9.5.5 Major Co-Development Deals 120

10 Global Pediatric Vaccines Market to 2017 - Appendix 122

10.1 Market Definitions 122

10.2 Abbreviations 122

10.3 Research Methodology 123

10.3.1 Global Pediatric Vaccines Market 123

10.3.2 Geographical Landscape 124

10.3.3 Therapeutic Landscape 125

10.3.4 Competitive Landscape 125

10.3.5 Pipeline Analysis 126

10.3.6 Strategic Consolidations 126

10.4 Contact Us 126

10.5 Disclaimer 126

10.6 Sources 127

List of Tables

Table 1: Pediatric Vaccine Market, Global, Vaccine Preventable Diseases, 2011 12

Table 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15

Table 3: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18

Table 4: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19

Table 5: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22

Table 6: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 24

Table 7: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25

Table 8: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2010 31

Table 9: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, %, 2008-2010 32

Table 10: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 39

Table 11: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 40

Table 12: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41

Table 13: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43

Table 14: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination($) , 2007-2017 44

Table 15: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45

Table 16: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49

Table 17: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50

Table 18: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51

Table 19: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55

Table 20: Polio Vaccines Market, Global, Average Cost of Vaccination ($) , 2007-2017 56

Table 21: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57

Table 22: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59

Table 23: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60

Table 24: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61

Table 25: Rotavirus Vaccines Market, Global, Comparison of Key Products, 2011 62

Table 26: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64

Table 27: DTaP Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 65

Table 28: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66

Table 29: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007–2017 69

Table 30: MMR Vaccines Market, Global, Average Cost of Vaccination($), 2007–2017 70

Table 31: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71

Table 32: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74

Table 33: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75

Table 34: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76

Table 35: Hepatitis A Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 77

Table 36: Hepatitis A Therapeutics Market, Global, Phase III Molecules, 2011 77

Table 37: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 78

Table 38: Hepatitis B Therapeutics Market, Global, Preclinical Pipeline Molecules, 2011 78

Table 39: Hepatitis B Therapeutics Market, Global, Phase I Molecules, 2011 79

Table 40: Hepatitis B Therapeutics Market, Global, Phase II Molecules, 2011 80

Table 41: Hepatitis B Therapeutics Market, Global, Phase III Molecules, 2011 82

Table 42: Hepatitis B Therapeutics Market, Global, NDA Filed Molecules, 2011 83

Table 43: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 84

Table 44: Polio Therapeutics Market, Global, Phase II Molecules, 2011 84

Table 45: Polio Therapeutics Market, Global, Phase III Molecules, 2011 85

Table 46: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86

Table 47: Rotavirus Therapeutics Market, Global, Pre-Clinical Molecules, 2011 87

Table 48: Rotavirus Therapeutics Market, Global, Phase I Molecules, 2011 87

Table 49: Rotavirus Therapeutics Market, Global, Phase II Molecules, 2011 87

Table 50: Rotavirus Therapeutics Market, Global, Phase III Molecules, 2011 87

Table 51: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88

Table 52: DTaP Therapeutics Market, Global, Preclinical Molecules, 2011 89

Table 53: DTaP Therapeutics Market, Global, Phase I Molecules, 2011 89

Table 54: DTaP Therapeutics Market, Global, Phase II Molecules, 2011 90

Table 55: DTaP Therapeutics Market, Global, Phase III Molecules, 2011 91

Table 56: DTAP Therapeutics Market, Global, NDA Filed Molecules, 2011 91

Table 57: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92

Table 58: MMR Therapeutics Market, Global, Preclinical Molecules, 2011 93

Table 59: MMR Therapeutics Market, Global, Phase II Molecules, 2011 93

Table 60: MMR Therapeutics Market, Global, Phase II Molecules 93

Table 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102

Table 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103

Table 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104

Table 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105

Table 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106

Table 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107

Table 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108

Table 68: Pediatric Vaccines Market, Global, Major M&A Deals, 2004–2011 109

Table 69: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 111

Table 70: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112

Table 71: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113

Table 72: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114

Table 73: Pediatric Vaccines Market, Global, Major Licensing Deals, 2004–2011 115

Table 74: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117

Table 75: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118

Table 76: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119

Table 77: Pediatric Vaccines Market, Global, Major Co-Development Deals, 2004–2011 120

List of Figures

Figure 1: Pediatric Vaccines Market, Global, Manufacturing Process, 2011 13

Figure 2: Pediatric Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 15

Figure 3: Pediatric Vaccines Market, Global, Market Share by Disease Segment, 2010 16

Figure 4: Pediatric Vaccines Market, Global, Market Share by Geography, 2010 17

Figure 5: Pediatric Vaccines Market, Global, Target Population (million), 2007-2017 18

Figure 6: Pediatric Vaccines Market, Global, Immunization Coverage, (%), 2008-2010 19

Figure 7: Pediatric Vaccines Market, Global, Growth Drivers and Barriers, 2011 20

Figure 8: Pediatric Vaccines Market, The US, Revenue Forecasts ($bn), 2007-2017 22

Figure 9: Pediatric Vaccines Market, The US, Average Cost of Vaccination Per Child ($), 2011 23

Figure 10: Pediatric Vaccines Market, The US, Immunization Coverage, (%), 2008-2010 25

Figure 11: Pediatric Vaccines Market, The US, Immunization Schedule, 2011 26

Figure 12: Pediatric Vaccines Market. The US, Vaccine Development and Approval Process, 2011 27

Figure 13: Pediatric Vaccines Market, The US, Distribution of Vaccine Procurement (%) , 2011 28

Figure 14: Pediatric Vaccines Market, Top Five Countries of Europe, Revenue Forecasts ($bn), 2007-2017 29

Figure 15: Pediatric Vaccines Market, Top Five Countries of Europe, Average Cost of Vaccination Per Child ($), 2011 30

Figure 16: Pediatric Vaccines Market, Top Five Countries of Europe, Immunization Coverage, (%), 2008-2010 32

Figure 17: Pediatric Vaccines Market, The UK, Immunization Schedule, 2011 33

Figure 18: Pediatric Vaccines Market, France, Immunization Schedule, 2011 34

Figure 19: Pediatric Vaccines Market, Germany, Immunization Schedule, 2011 35

Figure 20: Pediatric Vaccines Market, Italy, Immunization Schedule, 2011 36

Figure 21: Pediatric Vaccines Market, Spain, Immunization Schedule, 2011 37

Figure 22: Pediatric Vaccines Market, Rest of the World, Revenue Forecasts ($bn), 2007-2017 38

Figure 23: Pediatric Vaccines Market, Rest of the World, Average Cost of Vaccination Per Child ($), 2011 39

Figure 24: Pediatric Vaccines Market, Rest of the World, Immunization Coverage, (%), 2008-2010 41

Figure 25: Hepatitis A Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 43

Figure 26: Hepatitis A Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 44

Figure 27: Hepatitis A Vaccines Market, Global, Target Population (million), 2007-2017 45

Figure 28: Hepatitis B Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 49

Figure 29: Hepatitis B Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 50

Figure 30: Hepatitis B Vaccines Market, Global, Target Population (million) , 2007-2017 51

Figure 31: Polio Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 55

Figure 32: Polio Vaccines Market, Global, Average Cost of Vaccination, ($), 2007-2017 56

Figure 33: Polio Vaccines Market, Global, Target Population (million), 2007-2017 57

Figure 34: Rotavirus Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 59

Figure 35: Rotavirus Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 60

Figure 36: Rotavirus Vaccines Market, Global, Target Population (million), 2007-2017 61

Figure 37: DTaP Vaccines Market, Global, Revenue Forecasts ($m), 2007-2017 64

Figure 38: DTaP Vaccines Market, Global, Average Cost of Vaccination($), 2007-2017 65

Figure 39: DTaP Vaccines Market, Global, Target Population (million), 2007-2017 66

Figure 40: MMR Vaccines Market, Global, Revenue Forecasts ($bn), 2007-2017 69

Figure 41: MMR Vaccines Market, Global, Average Cost of Vaccination ($), 2007-2017 70

Figure 42: MMR Vaccines Market, Global, Target Population (million), 2007-2017 71

Figure 43: Pediatric Vaccines Market, Global, Pipeline Molecules by Phase, (%), 2011 74

Figure 44: Pediatric Vaccines Market, Global, Pipeline Molecules by Indication, (%), 2011 75

Figure 45: Hepatitis A Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 76

Figure 46: Hepatitis B Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 77

Figure 47: Polio Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 83

Figure 48: Rotavirus Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 86

Figure 49: DTaP Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 88

Figure 50: MMR Therapeutics Market, Global, Pipeline Molecules by Phase, (%), 2011 92

Figure 51: Pediatric Vaccines Market, Global, Novartis, Company Profile, 2011 94

Figure 52: Pediatric Vaccines Market, Global, Novartis, SWOT Analysis, 2011 95

Figure 53: Pediatric Vaccines Market, Global, GlaxoSmithKline, Company Profile, 2011 96

Figure 54: Pediatric Vaccines Market, Global, GlaxoSmithKline, SWOT Analysis, 2011 97

Figure 55: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, Company Profile, 2011 97

Figure 56: Pediatric Vaccines Market, Global, Sanofi Pasteur MSD, SWOT Analysis, 2011 98

Figure 57: Pediatric Vaccines Market, Global, Merck, Company Profile, 2011 99

Figure 58: Pediatric Vaccines Market, Global, Merck, SWOT Analysis, 2011 100

Figure 59: Pediatric Vaccines Market, Global, Pfizer, Company Profile, 2011 100

Figure 60: Pediatric Vaccines Market, Global, Pfizer, SWOT Analysis, 2011 101

Figure 61: Pediatric Vaccines Market, Global, Deals by Type, (%), 2004-2011 102

Figure 62: Pediatric Vaccines Market, Global, Deals by Geography, (%), 2004-2011 103

Figure 63: Pediatric Vaccines Market, Global, M&A Deals, 2004-2011 104

Figure 64: Pediatric Vaccines Market, Global, M&A Deals by Indication (%), 2004-2011 105

Figure 65: Pediatric Vaccines Market, Global, M&A Deals by Year, 2004-2011 106

Figure 66: Pediatric Vaccines Market, Global, M&A Deals by Geography (%), 2004-2011 107

Figure 67: Pediatric Vaccines Market, Global, M&A Deals by Value (%), 2004-2011 108

Figure 68: Pediatric Vaccines Market, Global, Licensing Agreements by Indication (%), 2004-2011 110

Figure 69: Pediatric Vaccines Market, Global, Licensing Agreements by Year, 2004-2011 112

Figure 70: Pediatric Vaccines Market, Global, Licensing Agreements by Geography (%), 2004-2011 113

Figure 71: Pediatric Vaccines Market, Global, Licensing Agreements by Value (%), 2004-2011 114

Figure 72: Pediatric Vaccines Market, Global, Co-Development Deals by Indication (%), 2004-2011 117

Figure 73: Pediatric Vaccines Market, Global, Co-Development Deals by Year, 2004-2011 118

Figure 74: Pediatric Vaccines Market, Global, Co-Development Deals by Geography, 2004-2011 119

Companies Mentioned

Novartis

GlaxoSmithKline (GSK)

Sanofi Pasteur MSD

Merck

Pfizer

To order this report:

Drug_and_Medication Industry: Pediatric Vaccines Market to 2017- Strategic Focus on Partnering as Licensing and Co-Development Accounted for 69% of Deal-Making Activity from 2004-2011

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.